Hyderabad, India-based Aurobindo Pharma signed a definitive agreement to acquire certain assets from Sandoz Inc., U.S.A., a Novartis division, for a consideration of $900 million. The proposed acquisition will be on a debt-free and cash-free basis, and comprises the dermatology business and a portfolio of oral solid products along with commercial...